CDA | Evidence Driven
CDA | Evidence Driven

spesolimab

Details

Generic Name:
spesolimab
Project Status:
Pending
Therapeutic Area:
generalized pustular psoriasis (GPP)
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Call for patient/clinician input open:
Brand Name:
Spevigo
Project Line:
Reimbursement Review
Project Number:
SR0844-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Subcutaneous (prevention) - The prevention of generalized pustular psoriasis (GPP) flares in adults and pediatric patients 12 years of age and older who have a history of GPP flares. Intravenous (treatment) - The treatment of GPP flares with a GPPGA total score of ≥ 2.
Fee Schedule:
Pending
Indications:
​Spevigo (spesolimab for injection) is indicated for the treatment of generalized pustular psoriasis (GPP), including treatment and prevention of flares, in adults and pediatric patients 12 years of age and older.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : April 22, 2024